Which has better earnings & valuation, ASTH or HNGE?

Astrana Health has higher revenue and earnings than Hinge Health. Astrana Health is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrana Health $3.18B 0.63 $22.49M $0.82 43.76 Hinge Health $720.06M 10.94 -$528.26M $1.28 76.25

Does the media prefer ASTH or HNGE?

In the previous week, Hinge Health had 5 more articles in the media than Astrana Health. MarketBeat recorded 9 mentions for Hinge Health and 4 mentions for Astrana Health. Hinge Health's average media sentiment score of 0.59 beat Astrana Health's score of 0.11 indicating that Hinge Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrana Health 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hinge Health 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HIMS or ASTH?

In the previous week, Hims & Hers Health had 42 more articles in the media than Astrana Health. MarketBeat recorded 46 mentions for Hims & Hers Health and 4 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.11 beat Hims & Hers Health's score of 0.07 indicating that Astrana Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 4 Very Positive mention(s) 3 Positive mention(s) 36 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Astrana Health 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CHE or ASTH?

Chemed has higher earnings, but lower revenue than Astrana Health. Chemed is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.63 $265.24M $19.91 25.55 Astrana Health $3.18B 0.63 $22.49M $0.82 43.76

Is CHE or ASTH more profitable?

Chemed has a net margin of 10.60% compared to Astrana Health's net margin of 1.05%. Chemed's return on equity of 31.77% beat Astrana Health's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Astrana Health 1.05% 10.30% 3.67%

Does the media refer more to CHE or ASTH?

In the previous week, Chemed had 7 more articles in the media than Astrana Health. MarketBeat recorded 11 mentions for Chemed and 4 mentions for Astrana Health. Chemed's average media sentiment score of 0.13 beat Astrana Health's score of 0.11 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 2 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Astrana Health 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ASTH or RDNT?

Astrana Health has higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrana Health $3.18B 0.63 $22.49M $0.82 43.76 RadNet $2.04B 2.70 -$18.65M -$0.27 N/A

Is ASTH or RDNT more profitable?

Astrana Health has a net margin of 1.05% compared to RadNet's net margin of -0.93%. Astrana Health's return on equity of 10.30% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets Astrana Health 1.05% 10.30% 3.67% RadNet -0.93% 2.61% 0.91%

Does the media favor ASTH or RDNT?

In the previous week, RadNet had 1 more articles in the media than Astrana Health. MarketBeat recorded 5 mentions for RadNet and 4 mentions for Astrana Health. RadNet's average media sentiment score of 0.51 beat Astrana Health's score of 0.11 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrana Health 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ASTH or BLLN?

Astrana Health has higher revenue and earnings than Billiontoone. Astrana Health is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrana Health $3.18B 0.63 $22.49M $0.82 43.76 Billiontoone $305.11M 16.38 $7.45M $0.70 151.29

Does the media favor ASTH or BLLN?

In the previous week, Billiontoone had 11 more articles in the media than Astrana Health. MarketBeat recorded 15 mentions for Billiontoone and 4 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.11 beat Billiontoone's score of 0.08 indicating that Astrana Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrana Health 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Billiontoone 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Astrana Health (ASTH) Competitors

$35.88 +0.97 (+2.78%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$35.82 -0.06 (-0.17%)

As of 10/2/2026 07:30 PM Eastern

Compare

ASTH vs. HNGE, HIMS, CHE, RDNT, and BLLN

Should you buy Astrana Health stock or one of its competitors? Astrana Health's main competitors and comparable companies include Hinge Health (HNGE), Hims & Hers Health (HIMS), Chemed (CHE), RadNet (RDNT), and Billiontoone (BLLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Astrana Health compare to Hinge Health?

Astrana Health (NASDAQ:ASTH) and Hinge Health (NYSE:HNGE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Hinge Health has a net margin of 15.15% compared to Astrana Health's net margin of 1.05%. Hinge Health's return on equity of 51.60% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Hinge Health	15.15%	51.60%	14.16%

Astrana Health has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

52.8% of Astrana Health shares are held by institutional investors. 20.3% of Astrana Health shares are held by insiders. Comparatively, 18.9% of Hinge Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Astrana Health currently has a consensus price target of $49.88, suggesting a potential upside of 39.01%. Hinge Health has a consensus price target of $105.33, suggesting a potential upside of 7.92%. Given Astrana Health's higher probable upside, equities research analysts plainly believe Astrana Health is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Hinge Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Astrana Health has higher revenue and earnings than Hinge Health. Astrana Health is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.18B	0.63	$22.49M	$0.82	43.76
Hinge Health	$720.06M	10.94	-$528.26M	$1.28	76.25

In the previous week, Hinge Health had 5 more articles in the media than Astrana Health. MarketBeat recorded 9 mentions for Hinge Health and 4 mentions for Astrana Health. Hinge Health's average media sentiment score of 0.59 beat Astrana Health's score of 0.11 indicating that Hinge Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hinge Health	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hinge Health beats Astrana Health on 12 of the 17 factors compared between the two stocks.

How does Astrana Health compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Astrana Health (NASDAQ:ASTH) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Astrana Health has a net margin of 1.05% compared to Hims & Hers Health's net margin of -5.51%. Astrana Health's return on equity of 10.30% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
Astrana Health	1.05%	10.30%	3.67%

Hims & Hers Health has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Astrana Health has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 52.8% of Astrana Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 20.3% of Astrana Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Hims & Hers Health presently has a consensus target price of $32.43, indicating a potential upside of 11.98%. Astrana Health has a consensus target price of $49.88, indicating a potential upside of 39.01%. Given Astrana Health's stronger consensus rating and higher possible upside, analysts plainly believe Astrana Health is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hims & Hers Health has higher earnings, but lower revenue than Astrana Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.88	$128.37M	-$0.63	N/A
Astrana Health	$3.18B	0.63	$22.49M	$0.82	43.76

In the previous week, Hims & Hers Health had 42 more articles in the media than Astrana Health. MarketBeat recorded 46 mentions for Hims & Hers Health and 4 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.11 beat Hims & Hers Health's score of 0.07 indicating that Astrana Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	4 Very Positive mention(s)	3 Positive mention(s)	36 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Astrana Health	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Astrana Health beats Hims & Hers Health on 11 of the 16 factors compared between the two stocks.

How does Astrana Health compare to Chemed?

Chemed (NYSE:CHE) and Astrana Health (NASDAQ:ASTH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Chemed presently has a consensus price target of $554.60, indicating a potential upside of 9.03%. Astrana Health has a consensus price target of $49.88, indicating a potential upside of 39.01%. Given Astrana Health's stronger consensus rating and higher possible upside, analysts clearly believe Astrana Health is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Chemed has higher earnings, but lower revenue than Astrana Health. Chemed is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.63	$265.24M	$19.91	25.55
Astrana Health	$3.18B	0.63	$22.49M	$0.82	43.76

In the previous week, Chemed had 7 more articles in the media than Astrana Health. MarketBeat recorded 11 mentions for Chemed and 4 mentions for Astrana Health. Chemed's average media sentiment score of 0.13 beat Astrana Health's score of 0.11 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Astrana Health	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Astrana Health has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Chemed has a net margin of 10.60% compared to Astrana Health's net margin of 1.05%. Chemed's return on equity of 31.77% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Astrana Health	1.05%	10.30%	3.67%

95.9% of Chemed shares are held by institutional investors. Comparatively, 52.8% of Astrana Health shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 20.3% of Astrana Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Chemed beats Astrana Health on 9 of the 16 factors compared between the two stocks.

How does Astrana Health compare to RadNet?

Astrana Health (NASDAQ:ASTH) and RadNet (NASDAQ:RDNT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Astrana Health has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, RadNet has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Astrana Health has higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.18B	0.63	$22.49M	$0.82	43.76
RadNet	$2.04B	2.70	-$18.65M	-$0.27	N/A

52.8% of Astrana Health shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 20.3% of Astrana Health shares are held by company insiders. Comparatively, 5.1% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, RadNet had 1 more articles in the media than Astrana Health. MarketBeat recorded 5 mentions for RadNet and 4 mentions for Astrana Health. RadNet's average media sentiment score of 0.51 beat Astrana Health's score of 0.11 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrana Health currently has a consensus target price of $49.88, suggesting a potential upside of 39.01%. RadNet has a consensus target price of $90.00, suggesting a potential upside of 28.70%. Given Astrana Health's higher probable upside, equities analysts plainly believe Astrana Health is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Astrana Health has a net margin of 1.05% compared to RadNet's net margin of -0.93%. Astrana Health's return on equity of 10.30% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
RadNet	-0.93%	2.61%	0.91%

Summary

Astrana Health beats RadNet on 10 of the 17 factors compared between the two stocks.

How does Astrana Health compare to Billiontoone?

Astrana Health (NASDAQ:ASTH) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

52.8% of Astrana Health shares are held by institutional investors. 20.3% of Astrana Health shares are held by company insiders. Comparatively, 50.2% of Billiontoone shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Astrana Health has higher revenue and earnings than Billiontoone. Astrana Health is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.18B	0.63	$22.49M	$0.82	43.76
Billiontoone	$305.11M	16.38	$7.45M	$0.70	151.29

In the previous week, Billiontoone had 11 more articles in the media than Astrana Health. MarketBeat recorded 15 mentions for Billiontoone and 4 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.11 beat Billiontoone's score of 0.08 indicating that Astrana Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Billiontoone	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Astrana Health currently has a consensus target price of $49.88, suggesting a potential upside of 39.01%. Billiontoone has a consensus target price of $126.25, suggesting a potential upside of 19.22%. Given Astrana Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Astrana Health is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Billiontoone	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

Billiontoone has a net margin of 8.04% compared to Astrana Health's net margin of 1.05%. Astrana Health's return on equity of 10.30% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Billiontoone	8.04%	9.96%	5.35%

Summary

Astrana Health beats Billiontoone on 9 of the 15 factors compared between the two stocks.

Get Astrana Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASTH vs. The Competition

Export

Metric	Astrana Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.95B	$9.59B	$7.14B	$13.18B
Dividend Yield	N/A	2.61%	2.53%	16.78%
P/E Ratio	43.76	34.21	275.68	26.04
Price / Sales	0.63	5.39	661.92	103.09
Price / Cash	12.41	120.59	77.60	51.75
Price / Book	2.55	5.15	10.93	6.31
Net Income	$22.49M	$315.68M	$3.51B	$362.16M
7 Day Performance	-1.35%	-2.59%	-2.00%	-1.66%
1 Month Performance	-5.15%	-3.19%	-6.15%	-4.50%
1 Year Performance	24.80%	7.93%	7.44%	2.06%

Astrana Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASTH Astrana Health	3.3806 of 5 stars	$35.88 +2.8%	$49.88 +39.0%	+29.2%	$1.95B	$3.18B	43.76	3,000
HNGE Hinge Health	3.7396 of 5 stars	$94.88 -0.4%	$105.33 +11.0%	+85.1%	$7.65B	$720.06M	74.08	1,437	Analyst Forecast
HIMS Hims & Hers Health	2.1918 of 5 stars	$30.13 +5.0%	$32.43 +7.7%	-50.0%	$7.03B	$2.58B	N/A	2,442	Trending News Insider Trade
CHE Chemed	3.452 of 5 stars	$508.05 -0.8%	$554.60 +9.2%	+15.2%	$6.63B	$2.53B	25.49	15,811	Insider Trade
RDNT RadNet	3.5607 of 5 stars	$69.34 -1.9%	$90.00 +29.8%	-10.7%	$5.46B	$2.04B	N/A	11,264	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASTH) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrana Health (ASTH) Competitors

ASTH vs. HNGE, HIMS, CHE, RDNT, and BLLN

How does Astrana Health compare to Hinge Health?

Summary

How does Astrana Health compare to Hims & Hers Health?

Summary

How does Astrana Health compare to Chemed?

Summary

How does Astrana Health compare to RadNet?

Summary

How does Astrana Health compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASTH vs. The Competition

Astrana Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Astrana Health (ASTH) Competitors

ASTH vs. HNGE, HIMS, CHE, RDNT, and BLLN

How does Astrana Health compare to Hinge Health?

Is ASTH or HNGE more profitable?

Which has more volatility & risk, ASTH or HNGE?

Do insiders & institutionals have more ownership in ASTH or HNGE?

Do analysts rate ASTH or HNGE?

Which has better earnings & valuation, ASTH or HNGE?

Does the media prefer ASTH or HNGE?

Summary

How does Astrana Health compare to Hims & Hers Health?

Is HIMS or ASTH more profitable?

Which has more risk & volatility, HIMS or ASTH?

Do institutionals and insiders hold more shares of HIMS or ASTH?

Do analysts prefer HIMS or ASTH?

Which has better earnings & valuation, HIMS or ASTH?

Does the media prefer HIMS or ASTH?

Summary

How does Astrana Health compare to Chemed?

Do analysts prefer CHE or ASTH?

Which has better valuation and earnings, CHE or ASTH?

Does the media refer more to CHE or ASTH?

Which has more volatility and risk, CHE or ASTH?

Is CHE or ASTH more profitable?

Do insiders & institutionals believe in CHE or ASTH?

Summary

How does Astrana Health compare to RadNet?

Which has more volatility & risk, ASTH or RDNT?

Which has stronger valuation and earnings, ASTH or RDNT?

Do institutionals and insiders have more ownership in ASTH or RDNT?

Does the media favor ASTH or RDNT?

Do analysts recommend ASTH or RDNT?

Is ASTH or RDNT more profitable?

Summary

How does Astrana Health compare to Billiontoone?

Do institutionals and insiders have more ownership in ASTH or BLLN?

Which has stronger valuation and earnings, ASTH or BLLN?

Does the media favor ASTH or BLLN?

Do analysts recommend ASTH or BLLN?

Is ASTH or BLLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASTH vs. The Competition

Astrana Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools